Sign Up to like & get
recommendations!
2
Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.3547
Abstract: Importance Angiosarcoma is a rare sarcoma subtype with a poor outcome. Carotuximab plus pazopanib produced a median progression-free survival (PFS) of 7.8 months in pazopanib-naive patients with chemotherapy-refractory angiosarcoma in a phase 1/2 trial. Objective…
read more here.
Keywords:
pazopanib alone;
trial;
carotuximab plus;
advanced angiosarcoma ... See more keywords